Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET
| Autor: | Vesa Oikonen, Olli Eskola, Juha E. Jääskeläinen, Martti Kulvik, Kaisa Lehtiö, Katja Havu-Aurén, Johanna Kiiski, Jyrki Vähätalo, Heikki Minn, Ville Vuorinen |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Boron Compounds Male inorganic chemicals Neurofibromatoses Phenylalanine medicine.medical_treatment Boron Neutron Capture Therapy Schwannoma Meningioma Stereotactic radiotherapy Tumour tissue Meningeal Neoplasms otorhinolaryngologic diseases Humans Medicine Radiology Nuclear Medicine and imaging Neurofibromatosis Brain Neoplasms business.industry General Medicine Middle Aged medicine.disease Radiation therapy Positron-Emission Tomography Female Radiopharmaceuticals business Nuclear medicine Neurilemmoma |
| Zdroj: | European Journal of Nuclear Medicine and Molecular Imaging. 34:87-94 |
| ISSN: | 1619-7089 1619-7070 |
| Popis: | Meningiomas and schwannomas associated with neurofibromatosis 2 (NF2) are difficult to control by microsurgery and stereotactic radiotherapy alone. Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue. PET with the boron carrier 4-borono-2-[(18)F]fluoro-L-phenylalanine ([(18)F]FBPA) allows investigation of whether 4-borono-L-phenylalanine (BPA) concentrates in NF2 tumours, which would make BNCT feasible.We studied dynamic uptake of [(18)F]FBPA in intracranial meningiomas (n=4) and schwannomas (n=6) of five sporadic and five NF2 patients. Tracer input function and cerebral blood volume were measured. [(18)F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis. These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [(18)F]FBPA tissue activity gradients.Model fits with three parameters K (1) (transport), k (2) (reverse transport) and k (3) (intracellular metabolism) were found to best illustrate [(18)F]FBPA uptake kinetics. Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status. The increased uptake was due to higher transport of [(18)F]FBPA in tumour. In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [(18)F]FBPA influx constant (K (i) -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1-1.4.[(18)F]FBPA PET offers a viable means to evaluate BPA uptake in meningiomas and schwannomas in NF2. Based on our results on tumour uptake of [(18)F]FBPA, some of these benign neoplasms may be amenable to BNCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink